主页 > 生命科学 >
【JACC】糖尿病患者植入支架的随机对比研究：西
abstract：
Objectives: The aim of this study was to compare the effectiveness of sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES) in patients with diabetes mellitus (DM).
Background: Drug-eluting stent implantation significantly improved the angiographic and clinical outcomes compared with bare-metal stent implantation in diabetic patients. However, comparison of SES with PES in diabetic patients has not been sufficiently evaluated.
Methods: This prospective, multicenter, randomized study compared SES (n = 200) and PES implantation (n = 200) for diabetic patients (n = 400). The primary end point was in-segment restenosis at 6 months according to intention-to-treat principle.
Results: The 2 groups had similar baseline clinical and angiographic characteristics. Six-month in-stent (3.4% vs. 18.2%, p < 0.001) and in-segment restenosis (4.0% vs. 20.8%, p < 0.001) and 9-month target lesion revascularization (2.0% vs. 7.5%, p = 0.017) were significantly lower in the SES versus the PES group. The incidence of death (0% in SES vs. 0.5% in PES, p = 0.999) or myocardial infarction (0.5% in SES vs. 0.5% in PES, p = 0.999) at 9-month follow-up was not statistically different between the 2 groups. Major adverse cardiac events including death, myocardial infarction, and target lesion revascularization at 9 months (2.0% vs. 8.0%, p = 0.010) were lower in the SES versus the PES group.
Conclusions: Sirolimus-eluting stent implantation is superior in reducing angiographic restenosis and improving 9-month clinical outcomes in patients with DM and coronary artery disease compared with PES implantation.
来源：http://content.onlinejacc.org/cgi/content/abstract/52/9/727?etoc title：A Randomized Comparison of Sirolimus- Versus Paclitaxel-Eluting Stent Implantation in Patients With Diabetes Mellitus
糖尿病患者植入支架的随机对比研究：西罗莫司vs紫杉醇
abstract：
Objectives: The aim of this study was to compare the effectiveness of sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES) in patients with diabetes mellitus (DM).
摘要
目的 研究目的是比较糖尿病人（DM）的西罗莫司洗脱支架（SES）和紫杉醇洗脱支架(PES)的有效性。
Background: Drug-eluting stent implantation significantly improved the angiographic and clinical outcomes compared with bare-metal stent implantation in diabetic patients. However, comparison of SES with PES in diabetic patients has not been sufficiently evaluated.
背景 与光突金属相比，药物洗脱支架置入在糖尿病人中很明显改善血管造影和临床结果。然而，SES和PES在糖尿病人中还没有进行有效地估计。
Methods: This prospective, multicenter, randomized study compared SES (n = 200) and PES implantation (n = 200) for diabetic patients (n = 400). The primary end point was in-segment restenosis at 6 months according to intention-to-treat principle.
方法 前瞻性，多中心，随机试验来比较SES（n = 200）和PES（n = 200）植入。根据紧张治疗原则，最初的终点为6个月的n段再狭窄。
Results: The 2 groups had similar baseline clinical and angiographic characteristics. Six-month in-stent (3.4% vs. 18.2%, p < 0.001) and in-segment restenosis (4.0% vs. 20.8%, p < 0.001) and 9-month target lesion revascularization (2.0% vs. 7.5%, p = 0.017) were significantly lower in the SES versus the PES group. The incidence of death (0% in SES vs. 0.5% in PES, p = 0.999) or myocardial infarction (0.5% in SES vs. 0.5% in PES, p = 0.999) at 9-month follow-up was not statistically different between the 2 groups. Major adverse cardiac events including death, myocardial infarction, and target lesion revascularization at 9 months (2.0% vs. 8.0%, p = 0.010) were lower in the SES versus the PES group.
结果 两组有相同基线的临床和血管造影特征。6个月用支架 (3.4% vs. 18.2%, p < 0.001)和节段再狭窄（4.0% vs. 20.8%, p < 0.001)和9个月损伤目标重建血管(2.0% vs. 7.5%, p = 0.017)，SES组要比PES组明显降低。9个月后死亡(0% in SES vs. 0.5% in PES, p = 0.999)和心肌梗死(0.5% in SES vs. 0.5% in PES, p = 0.999) 的发病率在两组之间并无统计学差异。9个月后，主要的不良心脏事件包括死亡，心肌梗死和损伤目标血管重建(2.0% vs. 8.0%, p = 0.010)，在SES 要比 PES 组发生率更低。
Conclusions: Sirolimus-eluting stent implantation is superior in reducing angiographic restenosis and improving 9-month clinical outcomes in patients with DM and coronary artery disease compared with PES implantation.
结论 与PES相比较，西罗莫司植入支架更好地减少血管造影的再狭窄，同时改进DM和冠脉病患者9个月的临床结果 摘要
目的 研究目的是比较糖尿病人（DM）的西罗莫司洗脱支架（SES）和紫杉醇洗脱支架(PES)的有效性。
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-03-13 17:14
医学,生命科学网